Clinical trial
A Phase 1/2 Study to Assess the Safety And Efficacy Of OCU410 For Geographic Atrophy Secondary To Dry Age-Related Macular Degeneration
NCT06018558 is registered in ClinicalTrials.gov with Ocugen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2 Study to Assess the Safety And Efficacy Of OCU410 For Geographic Atrophy Secondary To Dry Age-Related Macular Degeneration
- Lead sponsor
- Ocugen
- Phase
- Phase 1/2
- Overall status
- Active, not recruiting
- Start date
- February 23, 2023
- Completion date
- February 3, 2030
- Enrollment
- 60 (actual)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.